Cancer cells can develop resistance to anthracyclines through various mechanisms, including increased drug efflux via P-glycoprotein, enhanced DNA repair capabilities, and alterations in cell death pathways. Understanding these mechanisms is crucial for developing strategies to overcome resistance and improve therapeutic outcomes.
